Does comorbid disruptive behavior modify the effects of atomoxetine on ADHD symptoms as measured by a continuous performance test and a motion tracking device?

• Verfasst von: Wehmeier, Peter M. [VerfasserIn]
• Verfasst von: Banaschewski, Tobias [VerfasserIn]
• Verfasst von: Dittmann, Ralf [VerfasserIn]
• Titel: Does comorbid disruptive behavior modify the effects of atomoxetine on ADHD symptoms as measured by a continuous performance test and a motion tracking device?
• Verf.angabe: Peter M. Wehmeier, Laura Kipp, Tobias Banaschewski, Ralf W. Dittmann, and Alexander Schacht
• Jahr: 2015
• Umfang: 12 S.
• Fussnoten: Gesehen am 15.03.2018
• Titel Quelle: Enthalten in: Journal of attention disorders
• Ort Quelle: Thousand Oaks, Calif. : Sage, 1996
• Jahr Quelle: 2015
• Band/Heft Quelle: 19(2015), 7, Seite 591-602
• ISSN Quelle: 1557-1246
• DOI: doi:10.1177/1087054712456739
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1571091467

Abstract

Objective: To compare the reduction of ADHD symptoms under atomoxetine in patients with and without comorbid oppositional defiant disorder (ODD) or conduct disorder (CD) using a computer-based continuous performance test (cb-CPT) combined with an infrared motion tracking (MT) device. Method: Secondary analysis of a placebo-controlled study in ADHD patients (6-12 years old) treated with atomoxetine (target dose: 1.2 mg/kg per day). Cb-CPT/MT scores were analyzed using ANCOVA (last observation carried forward [LOCF]). Results: The data (N = 125) suggested a more pronounced atomoxetine effect in the group with comorbid ODD/CD as measured by all cb-CPT/MT parameters except for “normalized variation of reaction time” (nVRT). Conclusion: The results showed that atomoxetine reduced ADHD severity as measured by cb-CPT and MT parameters regardless of whether comorbid ODD/CD was present. The treatment effect of atomoxetine on hyperactivity appears to be more pronounced in the subgroup of patients with comorbid ODD/CD than in the subgroup without this comorbidity.